Metabolic syndrome: A closer look at the growing epidemic and its associated pathologies

Obesity Reviews

Volumn 16, Issue 1, 2015, Pages 1-12

  O'Neill, S ^a   O'Driscoll, L ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cancer; Cardiovascular disease; Metabolic syndrome; Type 2 diabetes mellitus

Indexed keywords

ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CHINA; COMORBIDITY; DENMARK; DISEASE ASSOCIATION; DYSLIPIDEMIA; EPIDEMIC; ETHNIC DIFFERENCE; FAMILY; GENETIC ASSOCIATION; GENETIC LINKAGE; HEART DISEASE; HUMAN; HYPERTENSION; INDIA; INSULIN RESISTANCE; IRELAND; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; SOUTH KOREA; UNITED STATES; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; HEALTH; NEOPLASMS; OBESITY, ABDOMINAL;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EPIDEMICS; GLOBAL HEALTH; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; NEOPLASMS; OBESITY, ABDOMINAL; PREVALENCE; RISK FACTORS;

EID: 84923190501     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12229     Document Type: Article

References (77)

1. Haller H, Hanefeld M. Synoptische Betrachtung Metabolischer Risikofaktoren. In: Haller H, Hanefeld M, Jaross W (eds). Lipidstoffwechselstörungen. Gustav Fischer Verlag: Jena, 1975, pp. 254-264.
2. Sookoian S, Pirola C. Metabolic syndrome: from the genetics to the pathophysiology. Curr Hypertens Rep 2011; 13: 149-157.
3. Harris MF. The metabolic syndrome. Aust Fam Physician 2013; 42: 524-527.
4. Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J Assoc Physicians India 2006; 54: 797-810.
5. Cornier MA, Dabelea D, Hernandez TL etal. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
6. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
7. Alberti KG, Zimmet P. The metabolic syndrome: time to reflect. Curr Diab Rep 2006; 6: 259-261.
8. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; 5: 1-7.
9. Kaur JA. Comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
10. Pal S, Ellis V. The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity (Silver Spring) 2010; 18: 1354-1359.
11. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
12. Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999-2006. Diabetes Care 2011; 34: 216-219.
13. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-2749.
14. Zimmet PZ, Alberti KG, Shaw JE. Mainstreaming the metabolic syndrome: a definitive definition. Med J Aust 2005; 183: 175-176.
15. Cameron AJ, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007; 77: 471-478.
16. Waterhouse DF, McLaughlin AM, Sheehan F, O'Shea D. An examination of the prevalence of IDF- and ATPIII-defined metabolic syndrome in an Irish screening population. Ir J Med Sci 2009; 178: 161-166.
17. Jeppesen J, Hansen TW, Rasmussen S etal. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007; 49: 2112-2119.
18. Zhao Y, Yan H, Yang R etal. Prevalence and determinants of metabolic syndrome among adults in a rural area of Northwest China. PLoS ONE 2014; 9: e91578.
19. Gu D, Reynolds K, Wu X etal. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365: 1398-1405.
20. Sawant A, Mankeshwar R, Shah S etal. Prevalence of metabolic syndrome in urban India. Cholesterol 2011; 2011: 920983.
21. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007; 23: 127-134.
22. Lim S, Shin H, Song JH etal. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care 2011; 34: 1323-1328.
23. Lee WY, Park JS, Noh SY etal. Prevalence of the metabolic syndrome among 40, 698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004; 65: 143-149.
24. Stancakova A, Laakso M. Genetics of metabolic syndrome. Rev Endocr Metab Disord 2014. DOI 10.1007/s11154-014-9293-9.
25. Lin HF, Boden-Albala B, Juo SH etal. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. Diabetologia 2005; 48: 2006-2012.
26. Bellia A, Giardina E, Lauro D etal. 'The Linosa Study': epidemiological and heritability data of the metabolic syndrome in a Caucasian genetic isolate. Nutr Metab Cardiovasc Dis 2009; 19: 455-461.
27. Kissebah AH, Sonnenberg GE, Myklebust J etal. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A 2000; 97: 14478-14483.
28. Loos RJ, Katzmarzyk PT, Rao DC etal. Genome-wide linkage scan for the metabolic syndrome in the HERITAGE Family Study. J Clin Endocrinol Metab 2003; 88: 5935-5943.
29. Edwards KL, Hutter CM, Wan JY, Kim H, Monks SA. Genome-wide linkage scan for the metabolic syndrome: the GENNID study. Obesity (Silver Spring) 2008; 16: 1596-1601.
30. Frayling TM, Timpson NJ, Weedon MN etal. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894.
31. Speliotes EK, Willer CJ, Berndt SI etal. Association analyses of 249, 796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-948.
32. Loos RJ, Lindgren CM, Li S etal. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008; 40: 768-775.
33. Willer CJ, Speliotes EK, Loos RJ etal. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet 2009; 41: 25-34.
34. Sabatti C, Service SK, Hartikainen AL etal. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet 2009; 41: 35-46.
35. Polasek O, Marusic A, Rotim K etal. Genome-wide association study of anthropometric traits in Korcula Island, Croatia. Croat Med J 2009; 50: 7-16.
36. Wen W, Cho YS, Zheng W etal. Meta-analysis identifies common variants associated with body mass index in east Asians. Nat Genet 2012; 44: 307-311.
37. Zabaneh D, Balding DJ. A genome-wide association study of the metabolic syndrome in Indian Asian men. PLoS ONE 2010; 5: e11961.
38. Kraja AT, Vaidya D, Pankow JS etal. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes 2011; 60: 1329-1339.
39. Kristiansson K, Perola M, Tikkanen E etal. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. Circ Cardiovasc Genet 2012; 5: 242-249.
40. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158-161.
41. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
42. Organisation WH. Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. World Health Organisation: Geneva, 2009.
43. Finucane MM, Stevens GA, Cowan MJ etal. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
44. Go AS, Mozaffarian D, Roger VL etal. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
45. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
46. Brady MJ. IRS2 takes center stage in the development of type 2 diabetes. J Clin Invest 2004; 114: 886-888.
47. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
48. Bonora E. Insulin resistance as an independent risk factor for cardiovascular disease: clinical assessment and therapy approaches. Av Diabetol 2005; 21: 255-261.
49. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
50. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005; 81: 358-366.
51. Albrink MJ, Krauss RM, Lindgrem FT etal. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids 1980; 15: 668-676.
52. Ruotolo G, Howard BV. Dyslipidemia of the metabolic syndrome. Curr Cardiol Rep 2002; 4: 494-500.
53. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286: H1597-H1602.
54. Duvnjak L, Bulum T, Metelko Z. Hypertension and the metabolic syndrome. Diabetol Croat 2008; 37: 83-89.
55. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep 2009; 11: 150-155.
56. Grundy SM, Cleeman JI, Daniels SR etal. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
57. Lee J, Ma S, Heng D etal. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. Diabetes Care 2007; 30: 343-347.
58. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286-288.
59. Athyros VG, Ganotakis ES, Tziomalos K etal. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010; 26: 713-719.
60. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
61. Lin Y, Sun Z. Current views on type 2 diabetes. J Endocrinol 2010; 204: 1-11.
62. Lebovitz HE. Type 2 diabetes: an overview. Clin Chem 1999; 45: 1339-1345.
63. Gregg EW, Cadwell BL, Cheng YJ etal. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004; 27: 2806-2812.
64. Song WJ, Mondal P, Wolfe A etal. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab 2014; 19: 667-681.
65. D'Alessio D. The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 2011; 13(Suppl. 1): 126-132.
66. Yamaoka-Tojo M, Tojo T, Takahira N etal. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovasc Diabetol 2010; 9: 17.
67. Gallagher E, Novosyadlyy R, Yakar S, LeRoith D. The increased risk of cancer in obesity and type 2 diabetes: potential mechanisms. In: Poretsky L (ed.). Principles of Diabetes Mellitus. Springer: US, 2010, pp. 579-599.
68. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
69. Pavelka JC, Brown RS, Karlan BY etal. Effect of obesity on survival in epithelial ovarian cancer. Cancer 2006; 107: 1520-1524.
70. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009; 7: 279-288.
71. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36(Suppl. 2): S233-S239.
72. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
73. Arcidiacono B, Iiritano S, Nocera A etal. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012; 2012: 789174.
74. Kucharska-Newton AM, Rosamond WD, Schroeder JC etal. HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 2008; 61: 292-300.
75. Shor R, Wainstein J, Oz D etal. Low HDL levels and the risk of death, sepsis and malignancy. Clin Res Cardiol 2008; 97: 227-233.
76. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7: 1003-1015.
77. Klein BEK, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002; 25: 1790-1794.